Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic expected Q1 2027 (shifted from the previously estimated Q4 2026) Availability updated: Retatrutide remains investigational
Semaglutide can interact with diabetes medications and may interfere with the absorption of oral medications, so its essential to discuss all potential interactions
When contouring complements natural proportions, the results appear more harmonious
Each one exploits a different feature of the U.S
Watson et al
Sign up for our newsletter and become a Paula's Choice Member
